Autism Treatments – Clinical Research Trials

Balovaptan for Autism – a Multicentre Clinical Trial For Adults (ongoing)

Re:Cognition Health are currently recruiting patients aged 18+ for an adult autism clinical trial

The award-winning team at Re:Cognition Health are delighted to be launching new clinical trials for adult autism to find new medications to help individuals manage some of challenging symptoms such as helping with socialisation, stress, anxiety or aggression. To date, there are no approved medications that target these core symptoms and this clinical study aims to change this.

Adults with autism have a different sensory experience; seeing, hearing and feeling the world differently and they may sometimes find this challenging when socialising or communicating. This new trial is investigating whether Balovaptan, an oral vasopressin 1a receptor agonist, can help individuals with autism manage certain social and communication challenges. It will investigate whether the medication can block a hormone receptor in the brain which is responsible for some the adult autism symptoms.

They are looking for adults (aged over 18) with a diagnosis of autism to take part in clinical trials for new treatment.

For more information and to register visit: recognitionhealth.com/autism-treatment/ and recognitionhealth.com/autism-clinical-trials-for-adults/

A large European multi-centre Phase III trial is currently taking place in France and several other EU countries.

This study is investigating the effectiveness of bumetanide for treating core symptoms of autism. Several UK centres are expected to take part.

More details on bumetanide clinical trial for autism

Media article on bumetanide trial

Watch this space for further updates and additional UK centres taking part.

South London and Maudsley NHS Foundation Trust, provider of the widest range of mental health services in the UK, is looking for adults with autism to take part in a new drug trial.

Who can take part?

• Do you have autism spectrum disorder?
• Are you at least 18 years old?
• Do you have someone you see and speak to regularly, who would be willing and able to be your ‘study partner’?

If so, you may be able to take part in V1ADUCT!

Thousands of people all around the world take part in clinical trials every year. Without them, new treatments cannot be developed. In fact, every medication that you’ve ever taken will have been investigated in clinical trials first.

V1ADUCT is assessing an investigational medication to see if it can help adults with autism better manage the social and communication challenges that are at the heart of autism. To date, no medications have been approved to treat autism’s core symptoms. By taking part in the study you will help us increase understanding of adult autism as well as have the opportunity to take part in a 2-year extension of the trial.

To find out more and to register your interest contact the V1ADUCT team by email [email protected] or call them on 0207 848 1520.

Arbaclofen for improving social difficulties in autism (launching summer 2019)

Investigating possible associations between Central Sensitivity Syndromes (CSS) and Autism (survey, ongoing)

‘Central Sensitivity Syndrome’ is a relatively new umbrella term used to describe a group of related illnesses including Fibromyalgia (FMS), Chronic Fatigue Syndrome (CFS), Temporomandibular Joint Disorder (TMJ), Irritable Bowel Syndrome (IBS) and several other conditions. Informal observations have suggested that autistic people might be more vulnerable to developing these conditions.

“The aim of the CENSSAS study is to see whether there is an association and, if so, what common complaints or overlapping symptoms there might be. To do this, we need to explore the symptoms of people with ASC and with CSS, but also look at the extent to which symptoms of CSS, autistic traits or other related symptoms occur in the broader population. Therefore, we are seeking participation from anyone aged 18+.”

For more information and to take part visit censsas.co.uk